Cargando…
Protein modeling and clinical description of a novel in‐frame GLB1 deletion causing GM1 gangliosidosis type II
BACKGROUND: Beta‐galactosidase‐1 ( GLB1) is a lysosomal hydrolase that is responsible for breaking down specific glycoconjugates, particularly GM1 (monosialotetrahexosylganglioside). Pathogenic variants in GLB1 cause two different lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharid...
Autores principales: | Richter, John E., Zimmermann, Michael T., Blackburn, Patrick R., Mohammad, Ahmed N., Klee, Eric W., Pollard, Laura M., Macmurdo, Colleen F., Atwal, Paldeep S., Caulfield, Thomas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305665/ https://www.ncbi.nlm.nih.gov/pubmed/30187681 http://dx.doi.org/10.1002/mgg3.454 |
Ejemplares similares
-
GM2 Gangliosidosis in Shiba Inu Dogs with an In‐Frame Deletion in HEXB
por: Kolicheski, A., et al.
Publicado: (2017) -
Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis
por: Latour, Yvonne L., et al.
Publicado: (2019) -
GM1 Gangliosidosis: Mechanisms and Management
por: Rha, Allisandra K, et al.
Publicado: (2021) -
Novel Pathogenic Variant in TGFBR2 Confirmed by Molecular Modeling Is a Rare Cause of Loeys-Dietz Syndrome
por: Zimmermann, Michael T., et al.
Publicado: (2017) -
Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
por: Allende, Maria L., et al.
Publicado: (2023)